Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Drug metab
MaoSRenJXuYLinJPanCMengYet al
)
Dcarie-Spain L, Fisette A, Zhu Z, et al
B.TrivediA.PfankuchT.RaberJ.WendlandM.et al (2009)
)
Packer recently proposed an intriguing hypothesis that DPP-4 inhibitors potentiate some endogenous peptides, such as stromal cell-derived factor-1, in addition to activation of GLP-1, and that unfavorable effects of those peptides on CV parameters (e.g., inflammation, fibrosis, plaque growth, and sympathetic activation) could prevail against the CV protective effects of GLP-1, possibly leading to worsened CV complications and HF [36, 37]
Design The researchers worked backwards from compounds already known to trigger growth-hormone release, hunting for the cell-surface receptor those compounds bound to, then cloned it
US$ 24.55
US$ 21.90
US$ 23.61
US$ 23.10
US$ 24.29
US$ 20.33
